MCID: NPH012
MIFTS: 59

Nephrotic Syndrome

Categories: Nephrological diseases, Genetic diseases, Rare diseases, Blood diseases, Immune diseases, Metabolic diseases, Endocrine diseases

Aliases & Classifications for Nephrotic Syndrome

MalaCards integrated aliases for Nephrotic Syndrome:

Name: Nephrotic Syndrome 12 76 37 29 55 6 44 15 40 73
Finnish Congenital Nephrotic Syndrome 73
Finnish Congenital Nephrosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1184
ICD10 33 N04 N04.9
ICD9CM 35 581
MeSH 44 D009404
NCIt 50 C34845
KEGG 37 H01657

Summaries for Nephrotic Syndrome

MalaCards based summary : Nephrotic Syndrome, also known as finnish congenital nephrotic syndrome, is related to sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis and pierson syndrome, and has symptoms including edema An important gene associated with Nephrotic Syndrome is NPHS2 (NPHS2, Podocin), and among its related pathways/superpathways are Interferon gamma signaling and Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Methylprednisolone and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Nephrotic syndrome is a collection of symptoms due to kidney damage. This includes protein in the urine,... more...

Related Diseases for Nephrotic Syndrome

Diseases in the Nephrotic Syndrome family:

Nephrotic Syndrome, Type 1 Nephrotic Syndrome, Type 4
Nephrotic Syndrome, Type 2 Nephrotic Syndrome, Type 3
Nephrotic Syndrome, Type 6 Nephrotic Syndrome, Type 7
Nephrotic Syndrome, Type 8 Nephrotic Syndrome, Type 9
Nephrotic Syndrome, Type 10 Nephrotic Syndrome, Type 11
Nephrotic Syndrome, Type 12 Nephrotic Syndrome, Type 13
Nephrotic Syndrome 14 Nephrotic Syndrome 15
Nephrotic Syndrome 16 Familial Nephrotic Syndrome

Diseases related to Nephrotic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
# Related Disease Score Top Affiliating Genes
1 sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 34.2 PLCE1 WT1
2 pierson syndrome 34.0 LAMB2 NPHS2
3 nephrotic syndrome, type 1 34.0 ACTN4 NPHS1 NPHS2 WT1
4 familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 33.9 NPHS1 PTPRO
5 lipoid nephrosis 33.8 ALB NPHS1 NPHS2
6 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 33.4 EMP2 NPHS1 NPHS2 PTPRO
7 familial nephrotic syndrome 33.2 ACTN4 ITGA3 NPHS1 NPHS2 PLCE1 WT1
8 denys-drash syndrome 33.0 NPHS1 NPHS2 WT1
9 familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 32.7 ARHGDIA NPHS1 NUP93 PLCE1 PTPRO WT1
10 galloway-mowat syndrome 32.6 ACTN4 LAMB2 NPHS1 NPHS2 NUP107
11 hypoparathyroidism, sensorineural deafness, and renal disease 32.4 ACTN4 LAMB2 NPHS1 NPHS2
12 membranous nephropathy 32.3 ALB B2M NPHS1 NPHS2
13 frasier syndrome 31.9 ACTN4 NPHS1 NPHS2 PLCE1 WT1
14 diffuse mesangial sclerosis 31.9 ARHGDIA LAMB2 NPHS1 NPHS2 PLCE1 WT1
15 glomerulonephritis 31.0 ALB NPHS1 NPHS2
16 focal segmental glomerulosclerosis 1 30.8 ACTN4 COQ8B NPHS1 NPHS2 NUP107 NUP205
17 kidney disease 30.8 ACTN4 ALB B2M NPHS1 NPHS2 WT1
18 iga glomerulonephritis 30.7 ALB NPHS1 NPHS2
19 crescentic glomerulonephritis 29.9 NPHS2 PTPRO WT1
20 familial lcat deficiency 29.9 ALB APOA1
21 focal segmental glomerulosclerosis 29.6 ACTN4 ALB COQ6 LAMB2 NPHS1 NPHS2
22 diffuse glomerulonephritis 29.4 ALB B2M
23 amyloidosis aa 29.2 APOA1 B2M
24 chronic kidney failure 28.7 ACTN4 ALB B2M NPHS1 NPHS2 WT1
25 nephrotic syndrome, type 5, with or without ocular abnormalities 12.3
26 nephrotic syndrome, type 2 12.3
27 nephrotic syndrome, type 3 12.3
28 congenital nephrotic syndrome finnish type 12.3
29 nephrotic syndrome, type 7 12.2
30 nephrotic syndrome, type 6 12.2
31 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.2
32 nephrotic syndrome, type 4 12.2
33 nephrotic syndrome, type 9 12.2
34 nephrotic syndrome 14 12.2
35 nephrotic syndrome, type 8 12.2
36 nephrotic syndrome, type 11 12.2
37 nephrotic syndrome, type 12 12.2
38 nephrotic syndrome 15 12.2
39 nephrotic syndrome, type 10 12.2
40 nephrotic syndrome, type 13 12.1
41 nephrotic syndrome 16 12.1
42 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 12.0
43 idiopathic steroid-sensitive nephrotic syndrome with focal segmental hyalinosis 12.0
44 nephrotic syndrome, idiopathic, steroid-resistant 11.9
45 sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 11.9
46 sporadic idiopathic steroid-resistant nephrotic syndrome with minimal changes 11.9
47 idiopathic steroid-sensitive nephrotic syndrome with minimal change 11.9
48 idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation 11.9
49 sporadic idiopathic steroid-resistant nephrotic syndrome with collapsing glomerulopathy 11.9
50 nephrotic syndrome ocular anomalies 11.8

Graphical network of the top 20 diseases related to Nephrotic Syndrome:



Diseases related to Nephrotic Syndrome

Symptoms & Phenotypes for Nephrotic Syndrome

UMLS symptoms related to Nephrotic Syndrome:


edema

MGI Mouse Phenotypes related to Nephrotic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 ACTN4 APOA1 ARHGDIA B2M EMP2 ITGA3
2 homeostasis/metabolism MP:0005376 10.1 ACTN4 ALB APOA1 ARHGDIA B2M COQ6
3 endocrine/exocrine gland MP:0005379 9.97 ACTN4 ALB APOA1 ARHGDIA B2M EMP2
4 mortality/aging MP:0010768 9.93 WT1 NPHS2 SGPL1 SMARCAL1 ACTN4 ALB
5 neoplasm MP:0002006 9.43 ACTN4 ALB B2M ITGA3 PLCE1 WT1
6 renal/urinary system MP:0005367 9.36 ACTN4 ALB ARHGDIA ITGA3 LAMB2 NPHS1

Drugs & Therapeutics for Nephrotic Syndrome

Drugs for Nephrotic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
2
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
6
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
8
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
12
Pravastatin Approved Phase 4,Phase 1 81093-37-0 54687
13
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
14
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
17
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 6221 5280795
18
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
19
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
21 Cyclosporins Phase 4,Phase 2
22 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
23 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
24 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
25 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
26 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Not Applicable
27 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Not Applicable
28 Vaccines Phase 4
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
31 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Protective Agents Phase 4,Phase 3,Not Applicable
41 Antirheumatic Agents Phase 4,Phase 2,Phase 3
42 Calcineurin Inhibitors Phase 4,Phase 2,Phase 3
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
46 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Antitubercular Agents Phase 4,Phase 3
48 Adrenocorticotropic Hormone Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 beta-endorphin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunoglobulin A Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
2 Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
3 Long Term Tapering or Standard Steroids for Nephrotic Syndrome Unknown status NCT00308321 Phase 4 long term tapering of prednisolone;standard prednisolone treatment
4 Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children Completed NCT01162005 Phase 4 Tacrolimus
5 Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Completed NCT01895894 Phase 4 Mycophenolate mofetil
6 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
7 A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
8 Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study Completed NCT01185197 Phase 4 Myfortic plus low-dose steroid;Prednisolone
9 Pharmacokinetics of Tacrolimus in Children Completed NCT03347357 Phase 4 Tacrolimus
10 Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes Completed NCT01021540 Phase 4 Repository corticotrophin
11 Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema Completed NCT02427880 Phase 4 Acetazolamide and Hydrochlorothiazide Followed by Furosemide;Furosemide and Hydrochlorothiazide Followed by Furosemide
12 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
13 Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) Completed NCT01028287 Phase 4 ACTH;ACTH
14 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Completed NCT02238418 Phase 4 Cholecalciferol vial (100 000 UI)
15 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
16 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome Recruiting NCT02382575 Phase 4 Rituximab;Tacrolimus
17 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Recruiting NCT00982072 Phase 4 tacrolimus;prednisolone
18 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
19 Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
20 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
21 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
22 Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome Not yet recruiting NCT02649413 Phase 4 Prednisone
23 ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children Not yet recruiting NCT03408405 Phase 4 Acthar Gel 80 UNT/ML Injectable Solution
24 Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study Terminated NCT00384618 Phase 4 pravastatin;vitamin E
25 Rituximab Trial for Pediatric Nephrotic Syndrome Unknown status NCT01716442 Phase 2, Phase 3 Rituximab;Placebo
26 Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
27 Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children Completed NCT01092962 Phase 3 Cyclophosphamide;Mycophenolate mofetil
28 Efficacy of Pentoxifylline on Primary Nephrotic Syndrome Completed NCT00354731 Phase 3 pentoxifylline;Corticosteroid
29 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Completed NCT02438982 Phase 3 Tacrolimus;Rituximab
30 Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
31 The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS) Completed NCT01309477 Phase 3 Tacrolimus Sustained-release Capsules (ADVAGRAF)
32 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
33 Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS) Completed NCT00615667 Phase 3 tacrolimus (FK506)
34 Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00981838 Phase 3 Rituximab
35 Steroid Treatment for Kidney Disease Completed NCT00065611 Phase 3 Oral dexamethasone
36 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
37 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
38 Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
39 Prednisolone Trial in Children Younger Than 4 Years Recruiting NCT03141970 Phase 3 Prednisolone
40 Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome Recruiting NCT03501459 Phase 3 Rituximab
41 Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children Recruiting NCT02818738 Phase 3 Levamisole Hydrochloride
42 Valproic Acid for Idiopathic Nephrotic Syndrome Recruiting NCT02896270 Phase 2, Phase 3 Valproic Acid
43 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
44 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome Active, not recruiting NCT02132195 Phase 3 ACTH
45 A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Active, not recruiting NCT02257697 Phase 3 Mizoribine (MZR);Cyclophosphamide (CTX)
46 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Active, not recruiting NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
47 Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome Not yet recruiting NCT03560011 Phase 2, Phase 3 immunoglobulin IV
48 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Not yet recruiting NCT03298698 Phase 3 Rituximab;Prednisone
49 Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome Terminated NCT02390362 Phase 3 Rituximab;MMF
50 IL-2 for Multi Drug Resistant Nephrotic Syndrome Completed NCT02455908 Phase 1, Phase 2 Proleukin®

Search NIH Clinical Center for Nephrotic Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: nephrotic syndrome

Genetic Tests for Nephrotic Syndrome

Genetic tests related to Nephrotic Syndrome:

# Genetic test Affiliating Genes
1 Nephrotic Syndrome 29

Anatomical Context for Nephrotic Syndrome

MalaCards organs/tissues related to Nephrotic Syndrome:

41
Kidney, T Cells, Lung, Bone, Testes, Liver, Endothelial

Publications for Nephrotic Syndrome

Articles related to Nephrotic Syndrome:

(show top 50) (show all 2088)
# Title Authors Year
1
Nephrotic syndrome complicated with femoral vein catheter-related phlegmasia cerulea dolens: A case report. ( 29436096 )
2018
2
Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand? ( 29389398 )
2018
3
Adrenocortical Suppression in Children with Nephrotic Syndrome Treated with Low-Dose Alternate Day Corticosteroids. ( 29962670 )
2018
4
Pulmonary Thromboembolism: A Rare but Serious Complication of Nephrotic Syndrome. ( 29962680 )
2018
5
Serum sickness with refractory nephrotic syndrome following treatment with rituximab. ( 29305810 )
2018
6
Chlormethine Hydrochloride is Not Inferior to Tacrolimus in Treating Steroid-Resistant Nephrotic Syndrome. ( 29402844 )
2018
7
Low birth weight is a conditioning factor for podocyte alteration and steroid dependance in children with nephrotic syndrome. ( 29350347 )
2018
8
Nail-Patella Syndrome: A Rare Cause of Nephrotic Syndrome in Pregnancy. ( 29515307 )
2018
9
Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome. ( 29421774 )
2018
10
Acute kidney injury complicating nephrotic syndrome of minimal change disease. ( 29980292 )
2018
11
Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. ( 29426974 )
2018
12
Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study. ( 29399079 )
2018
13
Spontaneous remission of adult-onset minimal change nephrotic syndrome associated with influenza B infection: a case report. ( 29973143 )
2018
14
Allergic bronchopulmonary aspergillosis presenting as nephrotic syndrome due to secondary amyloidosis: Case report and systematic review of the literature. ( 29970774 )
2018
15
Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. ( 29436729 )
2018
16
Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection? ( 29970751 )
2018
17
Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report. ( 29792170 )
2018
18
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy. ( 29568223 )
2018
19
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report andA review of the literaturea8c. ( 29393843 )
2018
20
Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome? ( 29959531 )
2018
21
Azithromycin suppressed relapses of idiopathic nephrotic syndrome in a child. ( 29423202 )
2018
22
Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO syndrome. ( 29877281 )
2018
23
BehAset's syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercepta8c. ( 29292692 )
2018
24
Plasma Cell Leukemia Masquerading as a Relapse of the Nephrotic Syndrome. ( 29401321 )
2018
25
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
26
Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report. ( 29939487 )
2018
27
Evaluation of interleukin-18 in children with steroid-sensitive nephrotic syndrome before and after using levamisole. ( 29970735 )
2018
28
Can Focal Segmental Glomerulosclerosis Be Differentiated From Minimal Change Nephrotic Syndrome Using Biomarkers? ( 29661342 )
2018
29
Lemmings into the sea or back across the bridge? The fate of albumin in nephrotic syndrome. ( 29389392 )
2018
30
Histopathological study of nephrotic syndrome in adults: A Moroccan report. ( 29970742 )
2018
31
<i>GAPVD1</i> and <i>ANKFY1</i> Mutations Implicate RAB5 Regulation in Nephrotic Syndrome. ( 29959197 )
2018
32
Correlation Between Single-Nucleotide Polymorphisms Within miR-30a and Related Target Genes and Risk or Prognosis of Nephrotic Syndrome. ( 29356585 )
2018
33
Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Questions. ( 29959530 )
2018
34
Successful treatment of rituximab- and steroid-resistant nephrotic syndrome with leukocytapheresis. ( 29341230 )
2018
35
Cytotoxic T- Lymphocyte Antigen-4 (CTLA4) Gene Expression and Urinary CTLA4 Levels in Idiopathic Nephrotic Syndrome. ( 29968132 )
2018
36
Nephrotic syndrome in very elderly: Should we treat aggressively? ( 29441190 )
2018
37
Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Answers. ( 29959533 )
2018
38
IL-23 Activated I^I' T Cells Affect Th17 Cells and Regulatory T Cells by Secreting IL-21 in Children with Primary Nephrotic Syndrome. ( 29119640 )
2018
39
Cryptococcosis as a cause of nephrotic syndrome? A case report and review of the literature. ( 29942774 )
2018
40
Predictors of poor outcome in children with steroid sensitive nephrotic syndrome. ( 29429831 )
2018
41
Portal Vein Thrombosis: A Rare Complication of Nephrotic Syndrome. ( 29962677 )
2018
42
A PRISMA-compliant systematic review and network meta-analysis on the efficacy between different regimens based on Tripterygium wilfordii Hook F in patients with primary nephrotic syndrome. ( 29979395 )
2018
43
Is medium dose of cyclosporine A effective in treatment of children with steroid-dependent nephrotic syndrome with reduction in corticosteroids dose consumption? ( 29948441 )
2018
44
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. ( 28090051 )
2017
45
Fibroblast Growth Factor 23 (FGF23) in untreated Nephrotic syndrome. ( 28087977 )
2017
46
Cavernous sinus thrombosis in a patient with nephrotic syndrome. ( 28516392 )
2017
47
Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome. ( 28864927 )
2017
48
Late Onset Cobalamin Disorder and Hemolytic Uremic Syndrome: A Rare Cause of Nephrotic Syndrome. ( 28835862 )
2017
49
Assessing responsiveness over time of the PROMIS(Ar) pediatric symptom and function measures in cancer, nephrotic syndrome, and sickle cell disease. ( 28884421 )
2017
50
A Drosophila model system to assess the function of human monogenic podocyte mutations that cause nephrotic syndrome. ( 28164240 )
2017

Variations for Nephrotic Syndrome

ClinVar genetic disease variations for Nephrotic Syndrome:

6
(show top 50) (show all 320)
# Gene Variation Type Significance SNP ID Assembly Location
1 TRPC6 NM_004621.5(TRPC6): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs869025541 GRCh38 Chromosome 11, 101504446: 101504446
2 TRPC6 NM_004621.5(TRPC6): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs869025541 GRCh37 Chromosome 11, 101375177: 101375177
3 LAMB2 NM_002292.3(LAMB2): c.5293G> A (p.Ala1765Thr) single nucleotide variant Benign/Likely benign rs74951356 GRCh38 Chromosome 3, 49121330: 49121330
4 LAMB2 NM_002292.3(LAMB2): c.5293G> A (p.Ala1765Thr) single nucleotide variant Benign/Likely benign rs74951356 GRCh37 Chromosome 3, 49158763: 49158763
5 LAMB2 NM_002292.3(LAMB2): c.4878G> A (p.Arg1626=) single nucleotide variant Uncertain significance rs148648480 GRCh37 Chromosome 3, 49159422: 49159422
6 LAMB2 NM_002292.3(LAMB2): c.4878G> A (p.Arg1626=) single nucleotide variant Uncertain significance rs148648480 GRCh38 Chromosome 3, 49121989: 49121989
7 LAMB2 NM_002292.3(LAMB2): c.4774C> T (p.Arg1592Trp) single nucleotide variant Benign/Likely benign rs61729458 GRCh38 Chromosome 3, 49122170: 49122170
8 LAMB2 NM_002292.3(LAMB2): c.4774C> T (p.Arg1592Trp) single nucleotide variant Benign/Likely benign rs61729458 GRCh37 Chromosome 3, 49159603: 49159603
9 LAMB2 NM_002292.3(LAMB2): c.4034G> A (p.Arg1345His) single nucleotide variant Conflicting interpretations of pathogenicity rs75073433 GRCh37 Chromosome 3, 49160755: 49160755
10 LAMB2 NM_002292.3(LAMB2): c.4034G> A (p.Arg1345His) single nucleotide variant Conflicting interpretations of pathogenicity rs75073433 GRCh38 Chromosome 3, 49123322: 49123322
11 LAMB2 NM_002292.3(LAMB2): c.3387A> G (p.Gln1129=) single nucleotide variant Likely benign rs34290943 GRCh37 Chromosome 3, 49161660: 49161660
12 LAMB2 NM_002292.3(LAMB2): c.3387A> G (p.Gln1129=) single nucleotide variant Likely benign rs34290943 GRCh38 Chromosome 3, 49124227: 49124227
13 LAMB2 NM_002292.3(LAMB2): c.2959G> A (p.Glu987Lys) single nucleotide variant Likely benign rs34759087 GRCh37 Chromosome 3, 49162284: 49162284
14 LAMB2 NM_002292.3(LAMB2): c.2959G> A (p.Glu987Lys) single nucleotide variant Likely benign rs34759087 GRCh38 Chromosome 3, 49124851: 49124851
15 LAMB2 NM_002292.3(LAMB2): c.2740G> A (p.Gly914Arg) single nucleotide variant Benign/Likely benign rs35713889 GRCh38 Chromosome 3, 49125150: 49125150
16 LAMB2 NM_002292.3(LAMB2): c.2740G> A (p.Gly914Arg) single nucleotide variant Benign/Likely benign rs35713889 GRCh37 Chromosome 3, 49162583: 49162583
17 LAMB2 NM_002292.3(LAMB2): c.1764C> T (p.Pro588=) single nucleotide variant Benign/Likely benign rs33942096 GRCh38 Chromosome 3, 49128787: 49128787
18 LAMB2 NM_002292.3(LAMB2): c.1764C> T (p.Pro588=) single nucleotide variant Benign/Likely benign rs33942096 GRCh37 Chromosome 3, 49166220: 49166220
19 LAMB2 NM_002292.3(LAMB2): c.1206G> A (p.Arg402=) single nucleotide variant Conflicting interpretations of pathogenicity rs201999373 GRCh38 Chromosome 3, 49130250: 49130250
20 LAMB2 NM_002292.3(LAMB2): c.1206G> A (p.Arg402=) single nucleotide variant Conflicting interpretations of pathogenicity rs201999373 GRCh37 Chromosome 3, 49167683: 49167683
21 LAMB2 NM_002292.3(LAMB2): c.1193C> T (p.Thr398Ile) single nucleotide variant Benign/Likely benign rs77500937 GRCh37 Chromosome 3, 49167696: 49167696
22 LAMB2 NM_002292.3(LAMB2): c.1193C> T (p.Thr398Ile) single nucleotide variant Benign/Likely benign rs77500937 GRCh38 Chromosome 3, 49130263: 49130263
23 LAMB2 NM_002292.3(LAMB2): c.306C> T (p.Asn102=) single nucleotide variant Benign/Likely benign rs79448908 GRCh37 Chromosome 3, 49169782: 49169782
24 LAMB2 NM_002292.3(LAMB2): c.306C> T (p.Asn102=) single nucleotide variant Benign/Likely benign rs79448908 GRCh38 Chromosome 3, 49132349: 49132349
25 PLCE1 NM_016341.3(PLCE1): c.513G> A (p.Val171=) single nucleotide variant Conflicting interpretations of pathogenicity rs61749239 GRCh38 Chromosome 10, 94031559: 94031559
26 PLCE1 NM_016341.3(PLCE1): c.513G> A (p.Val171=) single nucleotide variant Conflicting interpretations of pathogenicity rs61749239 GRCh37 Chromosome 10, 95791316: 95791316
27 PLCE1 NM_016341.3(PLCE1): c.810T> C (p.Cys270=) single nucleotide variant Benign rs17109671 GRCh38 Chromosome 10, 94031856: 94031856
28 PLCE1 NM_016341.3(PLCE1): c.810T> C (p.Cys270=) single nucleotide variant Benign rs17109671 GRCh37 Chromosome 10, 95791613: 95791613
29 PLCE1 NM_016341.3(PLCE1): c.960G> A (p.Glu320=) single nucleotide variant Benign rs17109674 GRCh37 Chromosome 10, 95791763: 95791763
30 PLCE1 NM_016341.3(PLCE1): c.960G> A (p.Glu320=) single nucleotide variant Benign rs17109674 GRCh38 Chromosome 10, 94032006: 94032006
31 PLCE1 NM_016341.3(PLCE1): c.1405T> A (p.Ser469Thr) single nucleotide variant Likely benign rs17508082 GRCh37 Chromosome 10, 95892129: 95892129
32 PLCE1 NM_016341.3(PLCE1): c.1405T> A (p.Ser469Thr) single nucleotide variant Likely benign rs17508082 GRCh38 Chromosome 10, 94132372: 94132372
33 PLCE1 NM_016341.3(PLCE1): c.1643G> T (p.Arg548Leu) single nucleotide variant Benign rs17417407 GRCh38 Chromosome 10, 94171330: 94171330
34 PLCE1 NM_016341.3(PLCE1): c.1643G> T (p.Arg548Leu) single nucleotide variant Benign rs17417407 GRCh37 Chromosome 10, 95931087: 95931087
35 PLCE1 NM_016341.3(PLCE1): c.1729G> A (p.Ala577Thr) single nucleotide variant Uncertain significance rs141639885 GRCh37 Chromosome 10, 95931173: 95931173
36 PLCE1 NM_016341.3(PLCE1): c.1729G> A (p.Ala577Thr) single nucleotide variant Uncertain significance rs141639885 GRCh38 Chromosome 10, 94171416: 94171416
37 PLCE1 NM_016341.3(PLCE1): c.2124G> A (p.Val708=) single nucleotide variant Benign/Likely benign rs61751496 GRCh38 Chromosome 10, 94234222: 94234222
38 PLCE1 NM_016341.3(PLCE1): c.2124G> A (p.Val708=) single nucleotide variant Benign/Likely benign rs61751496 GRCh37 Chromosome 10, 95993979: 95993979
39 PLCE1 NM_016341.3(PLCE1): c.3132C> T (p.His1044=) single nucleotide variant Likely benign rs61732522 GRCh37 Chromosome 10, 96012108: 96012108
40 PLCE1 NM_016341.3(PLCE1): c.3132C> T (p.His1044=) single nucleotide variant Likely benign rs61732522 GRCh38 Chromosome 10, 94252351: 94252351
41 PLCE1 NM_016341.3(PLCE1): c.4059C> T (p.Phe1353=) single nucleotide variant Likely benign rs61751499 GRCh37 Chromosome 10, 96025409: 96025409
42 PLCE1 NM_016341.3(PLCE1): c.4059C> T (p.Phe1353=) single nucleotide variant Likely benign rs61751499 GRCh38 Chromosome 10, 94265652: 94265652
43 PLCE1 NM_016341.3(PLCE1): c.4263G> A (p.Ser1421=) single nucleotide variant Likely benign rs41291134 GRCh38 Chromosome 10, 94265940: 94265940
44 PLCE1 NM_016341.3(PLCE1): c.4263G> A (p.Ser1421=) single nucleotide variant Likely benign rs41291134 GRCh37 Chromosome 10, 96025697: 96025697
45 PLCE1 NM_016341.3(PLCE1): c.4724G> C (p.Arg1575Pro) single nucleotide variant Benign rs2274224 GRCh38 Chromosome 10, 94279840: 94279840
46 PLCE1 NM_016341.3(PLCE1): c.4724G> C (p.Arg1575Pro) single nucleotide variant Benign rs2274224 GRCh37 Chromosome 10, 96039597: 96039597
47 PLCE1 NM_016341.3(PLCE1): c.5035+12C> A single nucleotide variant Benign rs3736901 GRCh38 Chromosome 10, 94284977: 94284977
48 PLCE1 NM_016341.3(PLCE1): c.5035+12C> A single nucleotide variant Benign rs3736901 GRCh37 Chromosome 10, 96044734: 96044734
49 PLCE1 NM_016341.3(PLCE1): c.5330C> T (p.Thr1777Ile) single nucleotide variant Benign rs3765524 GRCh38 Chromosome 10, 94298541: 94298541
50 PLCE1 NM_016341.3(PLCE1): c.5330C> T (p.Thr1777Ile) single nucleotide variant Benign rs3765524 GRCh37 Chromosome 10, 96058298: 96058298

Expression for Nephrotic Syndrome

Search GEO for disease gene expression data for Nephrotic Syndrome.

Pathways for Nephrotic Syndrome

Pathways related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.95 B2M NUP107 NUP205 NUP93
2 11.15 ACTN4 ITGA3 LAMB2 NPHS1 NPHS2 PLCE1
3
Show member pathways
11.13 NUP107 NUP205 NUP93
4 10.6 ACTN4 NPHS1

GO Terms for Nephrotic Syndrome

Cellular components related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 ACTN4 ALB APOA1 ARHGDIA B2M ITGA3
2 endoplasmic reticulum lumen GO:0005788 9.67 ALB APOA1 B2M LAMB2
3 nuclear pore GO:0005643 9.5 NUP107 NUP205 NUP93
4 slit diaphragm GO:0036057 9.16 NPHS1 NPHS2
5 host cell GO:0043657 9.13 NUP107 NUP205 NUP93
6 nuclear periphery GO:0034399 8.8 NUP107 NUP205 NUP93

Biological processes related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.84 ALB APOA1 B2M LAMB2
2 platelet degranulation GO:0002576 9.79 ACTN4 ALB APOA1
3 viral transcription GO:0019083 9.78 NUP107 NUP205 NUP93
4 mRNA transport GO:0051028 9.77 NUP107 NUP205 NUP93
5 mRNA export from nucleus GO:0006406 9.76 NUP107 NUP205 NUP93
6 regulation of gene silencing by miRNA GO:0060964 9.74 NUP107 NUP205 NUP93
7 protein sumoylation GO:0016925 9.73 NUP107 NUP205 NUP93
8 regulation of cellular response to heat GO:1900034 9.72 NUP107 NUP205 NUP93
9 intracellular transport of virus GO:0075733 9.63 NUP107 NUP205 NUP93
10 adrenal gland development GO:0030325 9.61 APOA1 WT1
11 mitotic nuclear envelope disassembly GO:0007077 9.61 NUP107 NUP205 NUP93
12 high-density lipoprotein particle remodeling GO:0034375 9.6 ALB APOA1
13 ubiquinone biosynthetic process GO:0006744 9.58 COQ6 COQ8B
14 regulation of glycolytic process GO:0006110 9.58 NUP107 NUP205 NUP93
15 nucleocytoplasmic transport GO:0006913 9.54 NUP107 NUP205 NUP93
16 blood vessel endothelial cell migration GO:0043534 9.52 APOA1 EMP2
17 glomerular basement membrane development GO:0032836 9.51 NPHS1 WT1
18 glomerular visceral epithelial cell development GO:0072015 9.49 NPHS1 NUP93
19 glomerular visceral epithelial cell differentiation GO:0072112 9.48 PTPRO WT1
20 tRNA export from nucleus GO:0006409 9.43 NUP107 NUP205 NUP93
21 regulation of glomerular filtration GO:0003093 9.32 EMP2 PTPRO
22 metanephric glomerular visceral epithelial cell development GO:0072249 9.16 LAMB2 NPHS2
23 nuclear pore complex assembly GO:0051292 9.13 NUP107 NUP205 NUP93
24 glomerulus development GO:0032835 8.8 PLCE1 PTPRO WT1

Molecular functions related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.26 ALB ARHGDIA
2 integrin binding GO:0005178 9.26 ACTN4 EMP2 ITGA3 LAMB2
3 structural constituent of nuclear pore GO:0017056 8.8 NUP107 NUP205 NUP93
4 protein binding GO:0005515 10.09 ACTN4 ALB APOA1 ARHGDIA B2M EMP2

Sources for Nephrotic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....